Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition
Sarah Aminov(Albert Einstein College of Medicine), Amit Verma(M.J.P. Rohilkhand University), Kith Pradhan(Albert Einstein College of Medicine), Orsi Giricz(Albert Einstein College of Medicine), Srinivas Aluri(Albert Einstein College of Medicine), Joshua Brody(New York University), Stefan K. Barta(University of Pennsylvania), William Matsui(The University of Texas at Austin), Nirali N. Shah(National Institutes of Health), Samir Parekh(The Ohio State University Wexner Medical Center), Bonnie Yates(National Institutes of Health), Shanisha Gordon(Albert Einstein College of Medicine), Carolina Schinke(University of Arkansas for Medical Sciences), Murali Janakiram(University of Minnesota), Beamon Agarwal(Providence College), Ulrich Steidl(Albert Einstein College of Medicine), Mendel Goldfinger(Albert Einstein College of Medicine), Hao‐Wei Wang(Fu Jen Catholic University), Yanhua Wang(Albert Einstein College of Medicine), Aditi Shastri(Albert Einstein College of Medicine), Veronika Polishchuk(Albert Einstein College of Medicine), Srabani Sahu(Albert Einstein College of Medicine), R. Alejandro Sica
Cited by 3
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
|Immunity|2016|1.2k
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744